LifeMD Q4 revenue rises but misses estimates

LifeMD

09/03/2026 20:24

Overview

Virtual primary care provider's Q4 revenue rose 4% but missed analyst expectations

Adjusted EBITDA for Q4 rose 348%, beating analyst expectations

Company launched oral Wegovy after year-end, boosting weight management patient growth

Outlook

LifeMD expects Q1 2026 revenue between $48 mln and $49 mln

Company anticipates Q1 adjusted EBITDA loss of $4 mln to $5 mln

LifeMD forecasts 2026 revenue between $220 mln and $230 mln

Result Drivers

INFRASTRUCTURE EXPANSION - Co's benefits infrastructure on track to cover 220 million Americans by Q2, supporting women's health growth

Company press release: ID:nGNX8rTbgQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$46.9 mln
$48.57 mln (8 Analysts)
Q4 EPS
$0.41
Q4 Adjusted EBITDA
Beat
$4.8 mln
$4.06 mln (7 Analysts)
Q4 Gross Margin
87%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LifeMD Inc is $8.50, about 183.3% above its March 6 closing price of $3.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)